Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $1.61 in the prior trading day, Autolus Therapeutics plc ADR (NASDAQ: AUTL) closed at $1.57, down -2.48%. In other words, the price has decreased by -$2.48 from its previous closing price. On the day, 1.57 million shares were traded. AUTL stock price reached its highest trading level at $1.62 during the session, while it also had its lowest trading level at $1.57.
Ratios:
Our goal is to gain a better understanding of AUTL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.03 and its Current Ratio is at 8.38. In the meantime, Its Debt-to-Equity ratio is 0.91 whereas as Long-Term Debt/Eq ratio is at 0.88.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on November 18, 2024, Upgraded its rating to Buy and sets its target price to $7.60 from $7 previously. On November 15, 2024, Redburn Atlantic Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $13.
On November 09, 2023, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $10.Deutsche Bank initiated its Buy rating on November 09, 2023, with a $10 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 16 ’24 when Martin Pule bought 698,741 shares for $4.23 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUTL now has a Market Capitalization of 417841376 and an Enterprise Value of 274059712. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.84 while its Price-to-Book (P/B) ratio in mrq is 1.61. Its current Enterprise Value per Revenue stands at 9.155 whereas that against EBITDA is -1.049.
Stock Price History:
The Beta on a monthly basis for AUTL is 1.87, which has changed by -0.5879265 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, AUTL has reached a high of $5.00, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is -29.83%, while the 200-Day Moving Average is calculated to be -25.63%.
Shares Statistics:
The stock has traded on average 2.25M shares per day over the past 3-months and 3396250 shares per day over the last 10 days, according to various share statistics. A total of 266.14M shares are outstanding, with a floating share count of 240.33M. Insiders hold about 9.70% of the company’s shares, while institutions hold 53.36% stake in the company. Shares short for AUTL as of 1755216000 were 14901573 with a Short Ratio of 6.61, compared to 1752537600 on 13657215. Therefore, it implies a Short% of Shares Outstanding of 14901573 and a Short% of Float of 7.380000000000001.
Earnings Estimates
The current assessment of Autolus Therapeutics plc ADR (AUTL) involves the perspectives of 6.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.13 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$0.52 and -$1.1 for the fiscal current year, implying an average EPS of -$0.84. EPS for the following year is -$0.66, with 7.0 analysts recommending between -$0.35 and -$1.01.
Revenue Estimates
For the next quarter, 8 analysts are estimating revenue of $26.51M. There is a high estimate of $37.11M for the next quarter, whereas the lowest estimate is $12.97M.
A total of 9 analysts have provided revenue estimates for AUTL’s current fiscal year. The highest revenue estimate was $97.13M, while the lowest revenue estimate was $43M, resulting in an average revenue estimate of $72.89M. In the same quarter a year ago, actual revenue was $10.12MBased on 9 analysts’ estimates, the company’s revenue will be $138.96M in the next fiscal year. The high estimate is $293.45M and the low estimate is $57.21M.
